N-substituted 4β-methyl-5-(3-hydroxyphenyl)-7α-amidomorphans are potent, selective κ opioid receptor antagonists

Journal of Medicinal Chemistry

Volumn 49, Issue 5, 2006, Pages 1781-1791

  Carroll, F Ivy ^a   Melvin, Matt S ^a   Nuckols, Michel C ^a   Mascarella, S Wayne ^a   Navarro, Hernán A ^a   Thomas, James B ^a  

^a RTI INTERNATIONAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 [3,4 DIHYDROISOQUINOLIN 2(1H) YL] N [5 (3 HYDROXYPHENYL) 4 METHYL 2 [2 (2 METHYLPHENYL)ETHYL] 2 AZABICYCLO[3.3.1]NON 7 YL]PROPANAMIDE; 4BETA METHYL 5 (3 HYDROXYPHENYL) 7ALPHA AMIDOMORPHAN; AMIDE; KAPPA OPIATE RECEPTOR; KAPPA OPIATE RECEPTOR ANTAGONIST; UNCLASSIFIED DRUG; 3 (3,4 DIHYDROISOQUINOLIN 2(1H) YL) N (5 (3 HYDROXYPHENYL) 4 METHYL 2 (2 (2 METHYLPHENYL)ETHYL) 2 AZABICYCLO(3.3.1)NON 7 YL)PROPANAMIDE; 3-(3,4-DIHYDROISOQUINOLIN-2(1H)-YL)-N-(5-(3-HYDROXYPHENYL)-4-METHYL-2-(2-(2-METHYLPHENYL)ETHYL)-2-AZABICYCLO(3.3.1)NON-7-YL)PROPANAMIDE; FUSED HETEROCYCLIC RINGS; GUANOSINE 5' O (3 THIOTRIPHOSPHATE);

ARTICLE; CHEMICAL MODIFICATION; DRUG POTENCY; DRUG SELECTIVITY; DRUG SYNTHESIS; SUBSTITUTION REACTION; ANIMAL; CHEMISTRY; CHO CELL; CRICETULUS; DRUG ANTAGONISM; HAMSTER; HUMAN; METABOLISM; RADIOASSAY; STRUCTURE ACTIVITY RELATION; SYNTHESIS;

ANIMALS; BICYCLO COMPOUNDS, HETEROCYCLIC; CHO CELLS; CRICETINAE; CRICETULUS; GUANOSINE 5'-O-(3-THIOTRIPHOSPHATE); HUMANS; RADIOLIGAND ASSAY; RECEPTORS, OPIOID, KAPPA; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 33644864111     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm058264p     Document Type: Article

References (22)

1. Zimmerman, D. M.; Nickander, R.; Horng, J. S.; Wong, D. T. New structural concepts for narcotic antagonists defined in a 4-phenylpiperidine series. Nature 1978, 275, 332-334.
2. Thomas, J. B.; Mascarella, S. W.; Rothman, R. B.; Partilla, J. S.; Xu, H.; McCullough, K. B.; Dersch, C. M.; Cantrell, B. E.; Zimmerman, D. M.; Carroll, F. I. Investigation of the N-substituent conformation governing potency and μ receptor subtype-selectivity in (+)-(3R,4R)-dimethyl-4-(3- hydroxyphenyl)piperidine opioid antagonists. J. Med. Chem. 1998, 41, 1980-1990.
3. Zimmerman, D. M.; Leander, J. D.; Cantrell, B. E.; Reel, J. K.; Snoddy, J.; Mendelsohn, L. G.; Johnson, B. G.; Mitch, C. H. Structure-activity relationships of the trans-3,4-dimethyl-4-(3-hydroxyphenyl)piperidine antagonists for μ and κ opioid receptors. J. Med. Chem. 1993, 36, 2833-2841.
4. Mitch, C. H.; Leander, J. D.; Mendelsohn, L. G.; Shaw, W. N.; Wong, D. T.; Cantrell, B. E.; Johnson, B. G.; Reel, J. K.; Snoddy, J. D.; Takemori, A. E.; Zimmerman, D. M. 3,4-Dimethyl-4-(3-hydroxyphenyl)piperidines: Opioid antagonists with potent anorectant activity. J. Med. Chem. 1993, 36, 2842-2850.
5. Zimmerman, D. M.; Gidda, J. S.; Cantrell, B. E.; Schoepp, D. D.; Johnson, B. G.; Leander, J. D. Discovery of a potent, peripherally selective trans-3,4-dimethyl-4-(3-hydroxyphenyl)piperidine opioid antagonist for the treatment of gastrointestinal motility disorders. J. Med. Chem. 1994, 37, 2262-2265.
6. Schmidt, W. K. Alvimopan* (ADL 8-2698) is a novel peripheral opioid antagonist. Am. J. Surg. 2001, 182, 27S-38S.
7. Leone, N.; Wentz, L. News Release from Adolor Corporation-FDA Accepts Entereg(TM) (alvimopan) New Drug Application (NDA) for Review. http://phx.corporate-ir.net/phoenix.zhtml?c=120919&p= irol- newsArticle&t=Regular&id=611171& (accessed 2004).
8. +-dependent high affinity binding of [3H]LYS15300, a 3,4-dimethyl-4-(3-hydroxyphenyl)piperidine opioid receptor inverse agonist. Eur. J. Pharmacol. 2003, 482, 139-150.
9. Thomas, J. B.; Fall, M. J.; Cooper, J. B.; Rothman, R. B.; Mascarella, S. W.; Xu, H.; Partilla, J. S.; Dersch, C. M.; McCullough, K. B.; Cantrell, B. E.; Zimmerman, D. M.; Carroll, F. I. Identification of an opioid κ receptor subtype-selective N-substituent for (+)-(3R,4R)-dimethyl-4-(3-hydroxyphenyl) piperidine. J. Med. Chem. 1998, 41, 5188-5197.
10. Thomas, J. B.; Atkinson, R. N.; Vinson, N. A.; Catanzaro, J. L.; Perretta, C. L.; Fix, S. E.; Mascarella, S. W.; Rothman, R. B.; Xu, H.; Dersch, C. M.; Cantrell, B. E.; Zimmerman, D. M.; Carroll, F. I. Identification of (3R)-7-hydroxy-N-((1S)-1-[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1- piperidinyl]methyl]-2-methylpropyl)-1,2,3,4-tetrahydro-3- isoquinolinecarboxamide as a novel potent and selective opioid kappa receptor antagonist. J. Med. Chem. 2003, 46, 3127-3137.
11. Thomas, J. B.; Atkinson, R. N.; Rothman, R. B.; Fix, S. E.; Mascarella, S. W.; Vinson, N. A.; Xu, H.; Dersch, C. M.; Lu, Y.; Cantrell, B. E.; Zimmerman, D. M.; Carroll, F. I. Identification of the first trans-(3R,4R)-dimethyl-4-(3- hydroxyphenyl)piperidine derivative to possess highly potent and selective opioid kappa receptor antagonist activity. J. Med. Chem. 2001, 44, 2687-2690.
12. Carroll, F. I.; Thomas, J. B.; Dykstra, L. A.; Granger, A. L.; Allen, R. M.; Howard, J. L.; Pollard, G. T.; Aceto, M. D.; Harris, L. S. Pharmacological properties of JDTic: A novel κ-opioid receptor antagonist. Eur. J. Pharmacol. 2004, 501, 111-119.
13. Beardsley, P. M.; Howard, J. L.; Shelton, K. L.; Carroll, F. I. Differential effects of the novel kappa opioid receptor antagonist, JDTic, on reinstatement of cocaine-seeking induced by footshock stressors vs cocaine primes and its antidepressant-like effects in rats. Psychopharmacology (Berlin) 2005, 183, 118-126.
14. Thomas, J. B.; Gigstad, K. M.; Fix, S. E.; Burgess, J. P.; Cooper, J. B.; Mascarella, S. W.; Cantrell, B. E.; Zimmerman, D. M.; Carroll, F. I. A stereoselective synthetic approach to N-alkyl-4β-methyl-5-phenylmorphans. Tetrahedron Lett. 1999, 40, 403-406.
15. Thomas, J. B.; Atkinson, R. N.; Namdev, N.; Rothman, R. B.; Gigstad, K. M.; Fix, S. E.; Mascarella, S. W.; Burgess, J. P.; Vinson, N. A.; Xu, H.; Dersch, C. M.; Cantrell, B. E.; Zimmerman, D. M.; Carroll, F. I. Discovery of an opioid kappa receptor selective pure antagonist from a library of N-substituted 4β-methyl-5-(3-hydroxyphenyl)morphans. J. Med. Chem. 2002, 45, 3524-3530.
16. Buck, J. S. Some Substituted Tetrahydroisoquinoline Hydrochlorides. J. Am. Chem. Soc. 1934, 56, 1769-1771.
17. Kucznierz, R.; Grams, F.; Leinert, H.; Marzenell, K.; Engh, R. A.; von der Saal, W. Tetrahydro-isoquinoline-based factor Xa inhibitors. J. Med. Chem. 1998, 41, 4983-4994.
18. Katritzky, A. R.; He, H.-Y.; Jiang, R.; Long, Q. 2-Substituted-1,2,3,4- tetrahydroisoquinolines and chiral 3-carboxyl analogues from N-benzotriazolylmethyl-N-phenethylamines. Tetrahedron: Asymmetry 2001, 12, 2427-2434.
19. Mandell, L.; Lee, D. E.; Courtney, L. F. Protection of a substituted catechol whose derivatives are subject to steric labilization. J. Org. Chem. 1982, 47, 731-734.
20. Mouloungui, Z.; Elmestour, R.; Delmas, M.; Gaset, A. Reactions de Wittig-Horner et de transesterification en une operation par activation anionique de liaisons C-H et O-H en milieu heterogene carbonate de potassium/alcool (Wittig-Horner reactions and trans-esterification by anionic activation of C-H and O-H in heterogeneous potassium carbonate/alcohol). Tetrahedron 1992, 48, 1219-1232.
21. Robertson, A.; Philp, D.; Neil Spencer, N. Recognition-induced control of a Diels-Alder cycloaddition. Tetrahedron 1999, 55, 11365-11384.
22. Carroll, F. I.; Chaudhari, S.; Thomas, J. B.; Mascarella, S. W.; Gigstad, K. M.; Deschamps, J.; Navarro, H. A. N-Substituted cis-4a-(3-hydroxyphenyl)-8a- methyloctahydroisoquinolines are opioid receptor pure antagonists. J. Med. Chem. 2005, 48, 8182-8193.